ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,342,560 shares of the biotechnology company's stock after acquiring an additional 435,480 shares during the period. ADMA Biologics makes up about 2.7% of Oberweis Asset Management Inc.'s portfolio, making the stock its 2nd largest holding. Oberweis Asset Management Inc. owned approximately 1.41% of ADMA Biologics worth $57,325,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ADMA. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics during the third quarter worth $61,858,000. Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics during the 4th quarter worth $19,076,000. EWG Elevate Inc. acquired a new stake in ADMA Biologics in the fourth quarter valued at about $480,000. Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. Finally, Veracity Capital LLC raised its stake in ADMA Biologics by 117.0% during the fourth quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock worth $796,000 after acquiring an additional 25,030 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

ADMA traded up $2.65 on Monday, reaching $24.51. The stock had a trading volume of 10,253,201 shares, compared to its average volume of 3,671,286. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $5.82 billion, a price-to-earnings ratio of 87.54 and a beta of 0.53. ADMA Biologics, Inc. has a fifty-two week low of $6.49 and a fifty-two week high of $25.62. The firm has a 50-day moving average of $18.80 and a 200-day moving average of $18.27.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.